The Valley Desk

Clinical trial reportJournal for immunotherapy of cancerPublished

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Fox Chase Cancer Center, Penn Medicine, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Journal for immunotherapy of cancer
Published
Subject terms
Humans; Melanoma; Carcinoma, Renal Cell; Kidney Neoplasms; Ipilimumab; Nivolumab; Immunotherapy; Renal cell carcinoma; Clinical Trials As Topic; Immune Checkpoint Inhibitors
PubMed ID
38604810
PubMed Central ID
PMC11015345
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal